Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy
- PDF / 346,551 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 177 Views
Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population Kai Li • Wusheng Li
Received: 19 June 2012 / Accepted: 25 August 2012 / Published online: 16 September 2012 Ó Springer Science+Business Media, LLC. 2012
Abstract The role of DNA repair gene polymorphisms in cancer development, progression, and response to treatment has received increased attention. We conducted a prospective study to determine whether associations exist between two polymorphisms in XRCC1 and ADPRT and the outcomes of Chinese ovarian cancer patients treated with platinum-based chemotherapy. A total of 335 new cases of ovarian cancer were consecutively collected between May 2005 and May 2007. Follow-up lasted for 4 years, and the outcome measure was survival time. Individuals carrying XRCC1 194Trp/Trp had a longer survival time than did those with the Arg/Arg genotype. Similarly, those carrying XRCC1 399 Gln/Gln genotypes had 0.44-fold the risk of death than those with the Arg/Arg genotype. The combination of XRCC1 194 Trp allele and 399 Gln allele could decrease the death risk of ovarian cancer. In summary, this study is the first to evaluate the associations between polymorphisms in DNA repair gene polymorphism and the risk of ovarian cancer in Chinese population. Our study found a significant association between XRCC1 Arg399Gln and XRCC1 Arg194Trp polymorphism and the clinical outcome of ovarian cancer. Furthermore, studies with larger sample sizes are still needed to confirm these associations in Chinese population. Keywords Ovarian cancer XRCC1 ADPRT Polymorphism Chinese population
K. Li (&) W. Li Department of Gynecologic Cancer, Shengjing Hospital of China Medical University, Shenyang, China e-mail: [email protected] W. Li e-mail: [email protected]
Introduction Ovarian cancer has the highest mortality rate among all female cancers worldwide; more than 50 % of the 21,650 women diagnosed with ovarian cancer annually die from this disease [1]. China has a relatively low incidence of 3–5/105 females, which is about one-fourth of the incidence in northern European countries [2]. More than 50 % of these cancer patients are usually diagnosed at an advanced stage [3]. Although several active chemotherapeutic agents are available, platinum-based doublet chemotherapy remains the standard initial treatment for ovarian cancer patients. Although the major prognostic factor for ovarian cancer is the cancer stage, there are differences in survival among ovarian cancer patients with similar disease stages. Recently, a number of studies have revealed that polymorphisms in certain genes, especially DNA repair genes, have a role in tumor response to chemotherapy and thus survival variability among individual patients. Therefore, better understanding of prognostic factors would be helpful in individualizing ovarian cancer treatment. The DNA repair gene products can recognize and repair damaged DNA induced by autologous cells or environmental agents. Impa
Data Loading...
